Want to join the conversation?
Drugmaker $ABBV reported a rise in 1Q16 earnings on higher revenue backed by continued momentum across rheumatology, dermatology and gastroenterology markets. Net income rose to $1.35Bil or $0.83 per share from $1.02Bil or $0.63 per share last year. Net revenues grew to $5.96Bil from $5.04Bil. Adjusted EPS increased to $1.15 from $0.94.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.
Well this is big! I don’t know if it’s someone’s monopoly or genuine excitement, but either way, $CSX is up 23% after market closed. I heard some activist investor is going to blow big money into CSX Corp. Anyone mind explaining?